Laser treatment of drusen to prevent progression to advanced age-related macular degeneration

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 10, 2015, Pages

  Virgili, Gianni ^a   Michelessi, Manuele ^b,c   Parodi, Maurizio B ^d   Bacherini, Daniela ^a   Evans, Jennifer R ^e  

^a UNIVERSITY OF FLORENCE   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGE RELATED MACULAR DEGENERATION; AUSTRALIA; CONTRAST SENSITIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUSEN; EUROPE; HUMAN; INFORMATION PROCESSING; LASER COAGULATION; NORTH AMERICA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; VISUAL ACUITY; VISUAL IMPAIRMENT; COMPLICATION; DISEASE COURSE; GEOGRAPHIC ATROPHY; MACULAR DEGENERATION; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINAL DRUSEN;

DISEASE PROGRESSION; GEOGRAPHIC ATROPHY; HUMANS; LASER COAGULATION; MACULAR DEGENERATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINAL DRUSEN; VISUAL ACUITY;

EID: 85016924607     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006537.pub3     Document Type: Review

References (97)

1. Alexander J, Elsner KS, Javornik NB, Whittock ER, Brightwell-Arnold M, Duncan JL, et al. Characteristics of exudation in patients with bilateral large drusen. Investigative Ophthalmology and Visual Science 2004;45:ARVO E-abstract 2989.
2. Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial. Ophthalmology 2006;113(11):1974-86.
3. Complications of Age-Related Macular Degeneration Prevention Trial Study Group. The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology. Clinical Trials 2004;1(1):91-107.
4. Figueroa M, Schocket LS, DuPont J, Metelitsina TI, Grunwald JE. Effect of laser treatment for dry age related macular degeneration on foveolar choroidal haemodynamics. British Journal of Ophthalmology 2004;88(6):792-5.
5. Figueroa M, Schocket LS, DuPont J, Metelitsina TI, Grunwald JE. Long-term effect of laser treatment for dry age-related macular degeneration on choroidal hemodynamics. American Journal of Ophthalmology 2006;141(5):863-7.
6. Grunwald JE, Figueroa M, Metelitsina TI, Schocket LS, DuPont JC. Effect of CAPT laser treatment on choroidal hemodynamics in age-related macular degeneration (AMD). Investigative Ophthalmology and Visual Science 2004;45:ARVO E-abstract 3133.
7. Maguire M, Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). Ophthalmology 2004;111(7):1307-16.
8. Sbarbaro JA, Maguire MG, CAPT Study Group. Annual changes in refractive error over 3 years among eyes with early AMD. Investigative Ophthalmology and Visual Science 2004;45:ARVO E-abstract 3055.
9. Stoltz RA, Ying GS, Alexander J, CAPT Study Group. Fundus features of untreated eyes with visual acuity loss in CAPT. Investigative Ophthalmology and Visual Science 2004;45:ARVO E-abstract 1389.
10. Ying GS, Liu C, Maguire MG, CAPT Research Group. Night-vision symptoms as a risk factor for vision loss and choroidal neovascularization in the Complications of Age-related Macular Degeneration Prevention Trial (CAPT). Investigative Ophthalmology and Visual Science 2005;46:ARVO E-abstract 204.
11. Anonymous. Choroidal neovascularization in the Choroidal Neovascularization Prevention Trial. The Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology 1998;105(8):1364-72.
12. Anonymous. Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial. Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology 1998;105(1):11-23.
13. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial. Ophthalmology 2003;110(5):971-8.
14. Fine SL, Maguire MG, Javornik NB, Ho AC, CNVPT Research Group. The Choroidal Neovascularization Prevention Trial (CNVPT): 4-year results. Investigative Ophthalmology and Visual Science 2001;42:ARVO Abstract 676.
15. Ho AC, Maguire MG, Yoken J, Lee MS, Shin DS, Javornik NB, et al. Laser-induced drusen reduction improves visual function at 1 year. Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology 1999;106(7):1367-73.
16. Ho AC, Yoken J, Lee MS, Shin DS, Javornik NB, Maguire MG, et al. Laser-induced drusen reduction improves visual function at one year. American Academy of Ophthalmology 1998:127.
17. Kaiser RS, Berger JW, Maguire MG, Ho AC, Javornik NB. Choroidal Neovascularization Prevention Trial Study Group. Laser burn intensity and the risk for choroidal neovascularization in the CNVPT Fellow Eye Study. Archives of Ophthalmology 2001;119(6):826-32.
18. Prenner JL, Rosenblatt BJ, Tolentino MJ, Ying GS, Javornik NB, Maguire MG, et al. Risk factors for choroidal neovascularization and vision loss in the fellow eye study of CNVPT. Retina 2003;23(3):307-14.
19. Regillo CD. Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial. Evidence-Based Eye Care 2003;4(4):204-5.
20. Rosenbaltt BJ, Prenner JL, Tolentino M, Ying G, Javornik NB, Maguire MG, et al. Predictors of visual acuity loss in the fellow eye study of the Choroidal Neovascularization Prevention Trial (CNVPT). Investigative Ophthalmology and Visual Science 2001;42:ARVO E-abstract 675.
21. Kertes PJ. Prophylactic laser treatment hastens choroidal neovascularization in unilateral age-related maculopathy: final results of the drusen laser study -commentary. Evidence-Based Ophthalmology 2006;7(3):135-7.
22. Owens SL, Bunce C, Brannon AJ, Wormald R, Bird AC, Drusen Laser Study Group. Prophylactic laser treatment appears to promote choroidal neovascularisation in high-risk ARM: results of an interim analysis. Eye 2003;17(5):623-7.
23. Owens SL, Bunce C, Brannon AJ, Xing W, Chisholm IH, Gross M, et al. Prophylactic laser treatment hastens choroidal neovascularization in unilateral age-related maculopathy: final results of the drusen laser study. American Journal of Ophthalmology 2006;141(2):276-81.
24. Owens SL, Guymer RH, Gross-Jendroska M, Bird AC. Fluorescein angiographic abnormalities after prophylactic macular photocoagulation for high-risk age-related maculopathy. American Journal of Ophthalmology 1999;127(6):681-7.
25. Figueroa MS, Regueras A, Bertrand J. Laser photocoagulation to treat macular soft drusen in age-related macular degeneration. Retina 1994;14(5):391-6.
26. Figueroa MS, Regueras A, Bertrand J, Aparicio MJ, Manrique MG. Laser photocoagulation for macular soft drusen. Updated results. Retina 1997;17(5):378-84.
27. Frennesson C, Nilsson SE. Prophylactic laser treatment in early age related maculopathy reduced the incidence of exudative complications. British Journal of Ophthalmology 1998;82(10):1169-74.
28. Frennesson CI. Prophylactic laser treatment in early age-related maculopathy: an 8-year follow-up in a randomized pilot study shows a reduced incidence of exudative complications. Acta Ophthalmologica Scandinavica 2003;81(5):449-54.
29. Frennesson IC, Nilsson SE. Effects of argon (green) laser treatment of soft drusen in early age-related maculopathy: a 6 month prospective study. British Journal of Ophthalmology 1995;79(10):905-9.
30. Frennesson IC, Nilsson SE. Laser photocoagulation of soft drusen in early age-related maculopathy (ARM). The one-year results of a prospective, randomised trial. European Journal of Ophthalmology 1996;6(3):307-14.
31. Frennesson CI, Bek T, Jaakkola A, Nilsson SE. Prophylactic Laser Treatment Study Group. Prophylactic laser treatment of soft drusen maculopathy: a prospective, randomized Nordic study. Acta Ophthalmologica 2009;87(7):720-4.
32. Bressler SB, Vitale S, Hawkins BS, Alexander J, Orr PR, Schachat AP, et al. Laser to Drusen Trial: an assessment of short term safety within randomized, prospective, controlled clinical trial. Investigative Ophthalmology and Visual Science 1995;36:ARVO E-abstract 1028.
33. Little HL, Showman J. A pilot randomized, controlled study on the effect of laser photocoagulation of confluent soft macular drusen. American Academy of Ophthalmology 1995:120.
34. Little HL, Showman JM, Brown BW. A pilot randomized controlled study on the effect of laser photocoagulation of confluent soft macular drusen. Ophthalmology 1997;104(4):623-31.
35. Olk RJ, Friberg TR, Stickney KL, Akduman L, Wong KL, Chen MC, et al. Therapeutic benefits of infrared (810-nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration: two-year results of a randomized pilot study. Ophthalmology 1999;106(11):2082-90.
36. Friberg TR, Brennen PM, Freeman WR, Musch DC, PTAMD Study Group. Prophylactic treatment of age-related macular degeneration report number 2: 810-nanometer laser to eyes with drusen: bilaterally eligible patients. Ophthalmic Surgery, Lasers and Imaging 2009;40(6):530-8.
37. Friberg TR, Musch DC, Lim JI, Morse L, Freeman W, Sinclair S, et al. Prophylactic treatment of age-related macular degeneration. Report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients. Ophthalmology 2006;113(4):612-22.
38. Rodanant N, Friberg TR, Cheng L, Aurora A, Bartsch D, Toyoguchi M, et al. Predictors of drusen reduction after subthreshold infrared (810 nm) diode laser macular grid photocoagulation for nonexudative age-related macular degeneration. American Journal of Ophthalmology 2002;134(4):577-85.
39. Guymer RH, Brassington KH, Dimitrov P, Makeyeva G, Plunkett M, Xia W, et al. Nanosecond-laser application in intermediate AMD: 12-month results of fundus appearance and macular function. Clinical and Experimental Ophthalmology 2014;2(5):466-79.
40. Huang YX, Xiang LN, Wang YL, Li MM, Hu YX. Long-term effect of prophylactic laser treatment for bilateral soft drusen. Chinese Medical Journal 2011;124(4):541-5.
41. Sarks SH, Arnold JJ, Killingsworth MC, Sarks JP. Early drusen formation in the normal and aging eye and their relation to age related maculopathy: a clinicopathological study. British Journal of Ophthalmology 1999;83(3):358-68.
42. Sigelman J. Foveal drusen resorption one year after perifoveal laser photocoagulation. Ophthalmology 1991;98(9):1379-83.
43. Sivagnanavel V, Chong V. Diffuse laser for drusen reduction in high risk age-related maculopathy. Investigative Ophthalmology and Visual Science 2004;45:ARVO E-abstract 3097.
44. Beaumont P, Kang HK, Gorbatov M, Do H, Matthew R. Prophylactic laser photocoagulation of drusen in early age-related macular degeneration. Clinical and Experimental Ophthalmology 2011;39(Suppl 1):23-41.
45. NCT01790802. A multi-centre, randomized trial into the safety and efficacy of nanosecond microsurgical laser intervention in early age-related macular degeneration. clinicaltrials.gov/show/NCT01790802 (accessed 12 August 2015).
46. Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Survey of Ophthalmology 1999;44(1):1-29.
47. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8. Archives of Ophthalmology 2001;119(10):1417-36.
48. Bressler NM, Silva JC, Bressler SB, Fine SL, Green WR. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. Retina 1994;14(2):130-42.
49. Bressler NM, Munoz B, Maguire MG, Vitale SE, Schein OD, Taylor HR, et al. Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities. Waterman study. Archives of Ophthalmology 1995;113(3):301-8.
50. Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J, et al. The burden of age-related macular degeneration: a value-based analysis. Current Opinion in Ophthalmology 2006;17(3):257-66.
51. Chakravarthy U, Stevenson M. Self-reported visual functioning and quality of life in age-related macular degeneration. Current Opinion in Ophthalmology 2005;16(3):179-83.
52. Chong EW, Wong TY, Kreis AJ, Simpson JA, Guymer RH. Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ 2007;335(7623):755.
53. Cleasby GW, Nakanishi AS, Norris JL. Prophylactic photocoagulation of the fellow eye in exudative senile maculopathy. A preliminary report. Modern Problems in Ophthalmology 1979;20:141-7.
54. Duvall J, Tso MO. Cellular mechanisms of resolution of drusen after laser coagulation. An experimental study. Archives of Ophthalmology 1985;103(5):694-703.
55. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology 2004;122(4):564-72.
56. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
57. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD000254.pub3]
58. Frennesson C, Nilsson SE. Prophylactic laser treatment in early age related maculopathy reduced the incidence of exudative complications. British Journal of Ophthalmology 1998;82(10):1169-74.
59. Gass JD. Drusen and disciform macular detachment and degeneration. Archives of Ophthalmology 1973;90(3):206-17.
60. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
61. GRADEpro GDT. GRADEpro Guideline Development Tool [Software]. McMasters University, 2015 (developed by Evidence Prime, Inc.). Available from www.gradepro.org.
62. Gross-Jendroska M, Owens SL, Flaxel CJ, Guymer RH, Bird AC. Prophylactic laser treatment to fellow eyes of unilateral retinal pigment epithelial tears. American Journal of Ophthalmology 1998;126(1):77-81.
63. Guidry C, Medeiros NE, Curcio CA. Phenotypic variation of retinal pigment epithelium in age-related macular degeneration. Investigative Ophthalmology and Visual Science 2002;43(1):267-73.
64. Guymer RH, Hageman GS, Bird AC. Influence of laser photocoagulation on choroidal capillary cytoarchitecture. British Journal of Ophthalmology 2001;85(1):40-6.
65. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443-57.
66. Hassell JB, Lamoureux EL, Keeffe JE. Impact of age related macular degeneration on quality of life. British Journal of Ophthalmology 2006;90(5):593-6.
67. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
68. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
69. Holz FG, Wolfensberger TJ, Piguet B, Gross-Jendroska M, Wells JA, Minassian DC, et al. Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors. Ophthalmology 1994;101(9):1522-8.
70. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. American Journal of Ophthalmology 2004;137(3):486-95.
71. Langan D, Higgins JP, Gregory W, Sutton AJ. Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis. Journal of Clinical Epidemiology 2012;65(5):511-9.
72. Lavinsky D, Cardillo JA, Melo LA Jr, Dare A, Farah ME, Belfort R Jr. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Investigative Ophthalmology and Visual Science 2011;52(7):4314-23.
73. Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Current Diabetes Reviews 2012;8(4):274-84.
74. Maguire M, Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). Ophthalmology 2004;111(7):1307-16.
75. Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM. Influence of age-related maculopathy on visual functioning and health-related quality of life. American Journal of Ophthalmology 1999;128(1):45-53.
76. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Archives of Ophthalmology 1997;115(6):741-7.
77. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?. British Journal of Ophthalmology 2003;87(3):312-7.
78. Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. British Journal of Ophthalmology 2012;96(5):752-6.
79. Parodi MB, Spasse S, Iacono P, Di Stefano G, Canziani T, Ravalico G. Subthreshold grid laser treatment of macular edema secondary to branch retinal vein occlusion with micropulse infrared (810 nanometer) diode laser. Ophthalmology 2006;113(12):2237-42.
80. Parodi MB, Iacono P, Ravalico G. Intravitreal triamcinolone acetonide combined with subthreshold grid laser treatment for macular oedema in branch retinal vein occlusion: a pilot study. British Journal of Ophthalmology 2008;92(8):1046-50.
81. Pauleikhoff D, Harper CA, Marshall J, Bird AC. Aging changes in Bruch's membrane. A histochemical and morphologic study. Ophthalmology 1990;97(2):171-8.
82. Pauleikhoff D, Chen JC, Chisholm IH, Bird AC. Choroidal perfusion abnormality with age-related Bruch's membrane change. American Journal of Ophthalmology 1990;109(2):211-7.
83. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology 2008;61(10):991-6.
84. Phipps JA, Guymer RH, Vingrys AJ. Loss of cone function in age-related maculopathy. Investigative Ophthalmology and Visual Science 2003;44(5):2277-83.
85. The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2014.
86. Rudnicka AR, Kapetanakis VV, Jarrar Z, Wathern AK, Wormald R, Fletcher AE, et al. Incidence of Late-Stage Age-Related Macular Degeneration in American Whites: Systematic Review and Meta-analysis. American Journal of Ophthalmology 2015;160:85-93.
87. Sarraf D, Gin T, Yu F, Brannon A, Owens SL, Bird AC. Long-term drusen study. Retina 1999;19(6):513-9.
88. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
89. Sivaprasad S, Elagouz M, McHugh D, Shona O, Dorin G. Micropulsed diode laser therapy: evolution and clinical applications. Survey of Ophthalmology 2010;55(6):516-30.
90. Smith W, Assink J, Kein R, Mitchell P, Klaver CCW, Klein BEK, et al. Risk factors for age-related macular degeneration. Pooled findings from three continents. Ophthalmology 2001;108(4):607-704.
91. StataCorp. 2013. Stata Statistical Software. Release 13. College Station, TX: StataCorp LP.
92. Vingerling JR, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration and smoking. The Rotterdam Study. Archives of Ophthalmology 1996;114(10):1193-6.
93. Wetzig PC. Photocoagulation of drusen-related macular degeneration: a long-term outcome. Transactions of the American Ophthalmological Society 1994;92:299-303.
94. White IR, Higgins JPT, Wood AM. Allowing for uncertainty due to missing data in meta-analyses. Part 1: two-stage methods. Statistics in Medicine 2008;27(5):711-27.
95. Young RW. Pathophysiology of age-related macular degeneration. Survey of Ophthalmology 1987;31(5):291-306.
96. Parodi MB, Evans JR. Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD006537]
97. Parodi MB, Virgili G, Evans JR. Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD006537.pub2]